In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc (GTHX), with a price target of $72. The company’s shares closed yesterday at $18.56, close to its 52-week low of $13.87.
White commented:
“We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.40/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 49.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $63.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.57 and a one-year low of $13.87. Currently, G1 Therapeutics Inc has an average volume of 283.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.